


Servier India inks partnership with MedGenome and Strand Life Sciences

11 November 2025 | News

To advance biomarker testing for IDH-mutated acute myeloid leukaemia and Cholangiocarcinoma



Servier India, a subsidiary of the leading French pharmaceutical company Servier Group, has announced the launch of a patient-centric biomarker testing initiative in collaboration with leading genomic laboratories MedGenome and Strand Life Sciences.

As part of this initiative, a customised panel of biomarker tests for Acute Myeloid Leukaemia (AML), an aggressive blood cancer and Cholangiocarcinoma (CCA), a rare bile duct cancer, is launched across India at subsidised rates making these advanced diagnostics more affordable and accessible.

The panel will be available to healthcare professionals across private and government sectors. Specifically, IDH1 and IDH2 mutation testing for AML and CCA, will be available free of cost for the government sector.

The patient-centric biomarker testing initiative aims to address access to good quality molecular testing which remains largely concentrated to a small subset of Indian population, majorly in urban centers, leaving many patients without timely and accurate diagnosis. This is the critical gap that Servier India aims to bridge.

The biomarker testing initiative is launched under 'Servier Care' patient support programme which offers comprehensive support to eligible patients, including financial assistance, free drug support and subsidised diagnostics, ensuring holistic care for patients throughout the treatment journey, where legally permissible.